pseudovirus
use
virolog
tool
safeti
versatil
howev
low
titer
virus
substanti
limit
wider
applic
develop
highli
effici
pseudoviru
product
system
capabl
yield
time
rabi
pseudoviru
tradit
method
employ
hightit
pseudovirus
develop
robust
vitro
vivo
neutral
assay
evalu
rabi
vaccin
tradit
reli
liveviru
base
assay
compar
current
rapid
fluoresc
focu
inhibit
test
rffit
vitro
pseudovirusbas
neutral
assay
pbna
much
less
laborintens
demonstr
better
reproduc
moreov
vivo
pbna
assay
also
found
superior
live
viru
base
assay
follow
intraven
administr
pseudoviru
effect
infect
mice
dynam
viral
distribut
sequenti
observ
spleen
liver
brain
furthermor
data
vivo
pbna
show
great
agreement
gener
live
viru
model
experiment
time
significantli
reduc
week
day
taken
togeth
effect
pseudoviru
product
system
facilit
develop
novel
pbna
assay
could
replac
live
virusbas
tradit
assay
due
safeti
rapid
reproduc
high
throughput
capac
rabi
remain
acut
zoonot
diseas
casefat
rate
approach
caus
almost
death
annual
major
case
found
asia
africa
although
lethal
diseas
rabi
could
effect
prevent
postexposur
prophylaxi
pep
regimen
specif
prompt
administr
vaccin
conjunct
rabiesimmunoglobulin
proper
wound
manag
exposur
prevent
rabi
even
highrisk
exposur
anim
studi
demonstr
rabiesspecif
antibodi
especi
neutral
antibodi
play
essenti
role
vaccinemedi
protect
yet
clinic
evalu
rabi
vaccin
human
possibl
due
ethic
consider
therefor
new
rabi
vaccin
rabiesspecif
immunoglobulin
must
evalu
potenc
vitro
vivo
assay
prior
author
human
use
current
assay
immunogen
determin
rabi
vaccin
immunoglobulin
sever
inher
limit
specif
vaccineinduc
natur
infectionelicit
antibodi
respons
rabi
viru
determin
use
serolog
assay
includ
rapid
fluoresc
focu
inhibit
test
rffit
fluoresc
antibodi
viru
neutral
favn
test
enzym
link
immunosorb
assay
elisa
current
gold
standard
vitro
assay
rffit
favn
routin
use
refer
laboratori
howev
assay
requir
use
live
rabi
virus
must
handl
biosafeti
level
contain
facil
although
inactiv
virus
use
coat
antigen
elisa
assay
use
assess
neutral
antibodi
vitro
neutral
assay
use
determin
rabi
vaccin
could
induc
neutral
antibodi
anim
result
gener
vitro
neutral
assay
alway
correl
vivo
protect
current
varieti
anim
model
use
evalu
new
rabi
vaccin
howev
live
virus
must
still
use
challeng
anim
immun
vaccin
anim
biosafeti
level
facil
taken
togeth
altern
assay
without
aforement
limit
explor
pseudoviru
wide
use
place
correspond
live
viru
serolog
screen
vaccin
efficaci
assess
gene
transduct
virolog
studi
viru
pseudoviru
capsid
encapsul
rna
genom
core
outer
membran
function
envelop
determin
tropism
viru
pseudoviru
pseudovirus
success
use
studi
varieti
envelop
virus
ebola
viru
middl
eastern
respiratori
syndrom
mer
viru
hepat
c
viru
influenza
viru
howev
technic
challeng
encount
investig
make
hightit
pseudovirus
specif
pseudotyp
lentivir
vector
rabv
glycoprotein
g
explor
experiment
gene
therapi
neurolog
disord
determin
neutral
antibodi
howev
low
transduct
effici
associ
glycoprotein
g
pseudotyp
viru
substanti
hinder
wider
applic
especi
true
vivo
anim
studi
rabi
pseudoviru
report
like
chimer
glycoprotein
vsvg
could
partial
resolv
transduct
issu
use
chimer
glycoprotein
would
compromis
applic
pseudoviru
analys
neutral
antibodi
target
envelop
wild
type
viru
clearli
novel
approach
explor
circumv
technic
difficulti
commun
present
novel
platform
capabl
gener
hightit
rabi
pseudoviru
high
qualiti
develop
novel
pseudovirusbas
neutral
assay
pbna
vitro
vivo
analys
rabiesspecif
immunoglobulin
vaccinesinduc
immunogen
demonstr
pseudovirusbas
assay
superior
current
assay
term
reproduc
safeti
turnaround
time
pseudoviru
vivo
assay
shorter
origin
viru
assay
optim
procedur
report
could
greatli
facilit
develop
similar
assay
replac
highli
pathogen
envelop
virus
assess
wider
rang
vaccin
gene
therapi
product
compar
effici
differ
promot
firefli
luciferas
fluc
gene
clone
gener
use
studi
control
three
addit
fluc
express
plasmid
contain
differ
promot
construct
replac
cmv
promot
ccmv
complet
cmv
promot
scmv
cag
ltr
gener
pscmvfluc
pcagfluc
pltrfluc
respect
cell
transfect
aforement
four
plasmid
rel
light
unit
rlu
analyz
hour
posttransfect
demonstr
highest
rlu
valu
construct
pscmvfluc
carri
complet
cmv
promotor
found
effect
drive
gene
express
note
wide
use
make
pseudotyp
viru
howev
low
titer
pseudovirus
make
unsuit
lot
experi
particularli
vivo
assay
requir
viral
titer
least
tuml
improv
titer
pseudoviru
introduc
env
rabi
pseudotyp
viru
env
previous
use
backbon
plasmid
valid
hiv
neutral
assay
high
titer
pseudotyp
virus
gener
howev
env
could
directli
use
make
rabi
gpseudotyp
viru
lack
report
gene
backbon
plasmid
therefor
clone
fluc
gene
env
end
silenc
env
gene
gener
envfluc
next
set
determin
optim
pair
g
protein
express
plasmid
differ
backbon
plasmid
fluc
gene
replac
cv
glycoprotein
gene
aforement
fluc
express
plasmid
differ
promot
gener
pscmvcv
c
pcagcv
pltrcv
l
respect
gener
variou
form
pseudovirus
n
envfluc
f
env
scmvfluc
fc
cotransfect
separ
four
g
protein
express
plasmid
cell
twelv
form
pseudotyp
virus
gener
subsequ
use
infect
cell
fortyeight
hour
postinfect
rlu
determin
found
pair
pcagcv
envscmvfluc
could
produc
highest
rlu
valu
data
shown
optim
condit
gener
envscmvfluc
test
ratio
pcagcv
envscmvfluc
end
ratio
pcagcv
envscmvfluc
rang
investig
found
ratio
ideal
yield
highest
titer
pseudotyp
viru
tcid
reach
high
tcid
ml
found
pcagcv
envscmvfluc
best
combin
next
investig
cell
type
gener
rabi
pseudoviru
achiev
seven
type
cell
test
includ
mdck
bsr
vero
titer
rabi
pseudoviru
gener
differ
cell
line
compar
use
oneway
analysi
varianc
anova
show
signific
differ
n
p
fig
cell
best
cell
substrat
pseudoviru
neutral
assay
next
determin
optim
number
cell
rabi
viru
product
toward
end
titrat
rabi
pseudotyp
viru
wide
rang
cell
number
found
yield
highest
titer
equal
concentr
viru
prepar
use
fig
titer
rabi
pseudoviru
detect
differ
cell
number
compar
use
oneway
anova
show
signific
differ
n
p
furthermor
pair
comparison
student
test
perform
signific
differ
p
observ
differ
scientif
report
doi
also
found
insignific
note
linear
correl
coeffici
r
obtain
cell
inoculum
found
greater
reveal
excel
linear
curv
fit
moreov
neutral
assay
perform
differ
cell
number
valu
maxim
inhibitori
concentr
ic
valu
similar
cell
inocula
rang
fig
howev
input
cell
number
less
variat
ic
valu
would
increas
dramat
given
find
chosen
subsequ
experi
optim
viru
dose
neutral
assay
next
test
viral
inocula
dose
rang
start
tcid
well
vitro
neutral
assay
chines
nation
refer
sampl
iuml
intern
control
sampl
design
sampl
iuml
rffit
assay
employ
viral
dose
optim
expect
absolut
ic
valu
decreas
gradual
increas
amount
viral
inocula
fig
b
c
furthermor
valu
sampl
assign
refer
sampl
titer
fell
within
accept
rang
viru
inocula
rang
highest
pseudoviru
titer
obtain
cell
panel
effect
cell
number
pseudoviru
titrat
cell
rabi
pseudotyp
viru
titrat
rang
cell
number
well
found
yield
highest
titer
equal
concentr
viru
prepar
use
panel
c
effect
cell
number
pseudoviru
neutral
assay
valu
maxim
inhibitori
concentr
ic
valu
similar
cell
inocula
rang
input
cell
number
less
variat
ic
valu
would
increas
dramat
scientif
report
doi
tcid
well
note
lower
viral
inocula
result
larger
variabl
less
curv
fit
smaller
r
valu
specif
although
titer
sampl
also
met
accept
criteria
lower
viral
inoculum
tcid
well
trend
increas
variabl
viral
inocula
less
tcid
well
fig
b
support
decreas
r
valu
therefor
chose
viral
inocula
tcid
well
optim
dose
process
also
determin
deaedextran
concentr
rang
gml
rlu
valu
found
increas
increas
amount
deaedextran
gml
rlu
read
plateau
deaedextran
concentr
gml
decreas
sharpli
concentr
deaedextran
reach
gml
decreas
rlu
valu
found
due
cellular
toxic
induc
deaedextran
specif
viabil
cell
decreas
deaedextran
concentr
reach
gml
higher
neutral
assay
although
addit
deaedextran
could
reduc
viru
volum
yield
similar
level
snr
littl
effect
final
result
base
observ
gml
deaedextran
chosen
enhanc
infecti
pseudoviru
without
caus
cytotox
sensit
reproduc
correl
pbna
rffit
pseudovirusbas
neutral
assay
pbna
assay
intend
use
analys
human
anim
sampl
panel
fifti
human
thirti
mous
serum
sampl
use
evalu
pbna
parallel
rffit
comparison
first
establish
limit
detect
lod
pbna
assay
shown
fig
assay
pbna
human
serum
sampl
found
higher
background
compar
mous
sampl
mean
titer
valu
neg
sampl
standard
deviat
sd
use
calcul
limit
detect
lod
lod
human
serum
sampl
mous
serum
sampl
compar
nation
antirabi
standard
iuml
lod
iuml
iuml
human
mous
serum
sampl
respect
valu
two
intern
control
sampl
initi
assign
use
rffit
test
time
individu
plate
iuml
iuml
b
mean
sd
reproduc
pbna
determin
test
two
intern
control
sampl
three
independ
run
run
reproduc
pbna
determin
test
two
intern
control
sampl
three
independ
run
run
two
sampl
test
time
individu
plate
coeffici
variat
cv
rang
intra
assay
inter
assay
two
sampl
test
time
individu
plate
duplic
well
coeffici
variat
cv
rang
intra
assay
inter
assay
fig
total
cv
sampl
b
pbna
respect
rel
lower
rffit
result
test
pbna
within
assign
valu
predetermin
rffit
base
result
gener
pbna
test
valu
rang
assign
sampl
iuml
b
iuml
determin
correl
pbna
rffit
qualit
analys
rabiesspecif
antibodi
serum
sampl
vaccin
human
subject
assay
among
clinic
sampl
identifi
posit
rffit
pbna
assay
respect
fig
qualit
comparison
result
two
assay
show
concord
posit
neg
sampl
kappa
respect
discord
found
seven
sampl
mcnemar
p
analysi
reveal
neutral
antibodi
valu
seven
sampl
determin
pbna
rffit
seven
valu
close
cutoff
valu
iuml
indic
discord
mainli
associ
serum
sampl
low
level
antibodi
ie
near
borderlin
set
posit
valu
correl
two
assay
also
determin
quantit
analys
human
sampl
end
serum
sampl
test
posit
assay
use
determin
correl
found
good
linear
correl
two
assay
r
p
fig
fit
regress
line
present
equat
pbna
ci
estim
slope
found
p
estim
intercept
p
compar
pbna
valu
rffit
valu
sampl
test
averag
recoveri
pbna
rsd
confirm
correl
two
assay
employ
blandaltman
model
end
differ
antibodi
concentr
sampl
log
iuml
log
iuml
rffit
plot
mean
valu
obtain
two
assay
fig
mean
differ
log
iuml
sd
differ
log
iuml
base
blandaltman
plot
limit
agreement
log
iuml
mean
sd
reveal
differ
posit
sampl
predetermin
assay
fall
within
limit
agreement
collect
data
indic
statist
strong
correl
pbna
rffit
qualit
quantit
analys
clinic
sampl
wherea
former
least
time
sensit
investig
whether
hightit
pseudotyp
viru
prepar
could
use
develop
vivo
assay
rabi
vaccin
evalu
conduct
anim
experi
mice
kunm
mice
km
inocul
pseudoviru
variou
rout
includ
intracrani
subcutan
intramuscular
intraven
inject
turn
intraven
inject
result
detect
bioluminesc
signal
fig
determin
optim
time
point
signal
detect
two
km
mice
inject
tcid
pseudoviru
monitor
six
hour
postinject
day
day
intens
signal
increas
reach
highest
level
next
investig
murin
strain
best
suitabl
vivo
assay
achiev
km
nih
balbc
intraven
inocul
amount
rabi
pseudotyp
viru
shown
fig
highest
signal
detect
km
mice
hour
postinject
also
determin
optim
weight
km
mice
vivo
assay
km
mice
bodi
weight
rang
gram
inocul
tcid
per
mous
shown
fig
lighter
bodi
weight
km
mice
higher
signal
could
detect
follow
intraven
iv
inject
therefor
conclud
intraven
inocul
km
mice
weigh
gram
chosen
conduct
rabi
vaccin
evalu
use
pseudoviru
experi
next
conduct
determin
optim
time
point
signal
detect
mice
follow
iv
inject
end
two
km
mice
inject
tcid
pseudoviru
six
hour
postinject
start
monitor
anim
bioluminesc
imag
day
bioluminesc
signal
visual
spleen
liver
one
day
postinocul
day
densiti
signal
increas
reach
highest
level
organ
signal
densiti
began
declin
two
tissu
day
spread
pseudoviru
brain
detect
three
day
postinject
signal
intens
declin
rapidli
complet
disappear
day
observ
larg
expect
given
pseudovir
infect
singleround
event
find
indic
h
postinfect
optim
time
point
vivo
assay
pbna
mous
model
use
wt
rabi
viru
final
compar
vivo
pseudoviru
assay
tradit
mous
assay
employ
wt
rabi
viru
first
determin
dose
pseudoviru
inocul
end
serial
dilut
pseudovirus
inject
intraven
seven
group
mice
micegroup
start
dose
anim
tcid
predetermin
pbna
shown
fig
anim
infecti
dose
aid
pseudoviru
found
tcid
vivo
protect
assay
pseudoviru
dose
determin
aid
equival
tcid
next
investig
correl
vivo
pbna
current
live
virusbas
mous
assay
toward
end
inject
rabiesspecif
immunoglobulin
km
mice
intramuscularli
three
day
challeng
either
wt
viru
pseudoviru
shown
fig
clear
doserespons
observ
pseudoviru
vivo
assay
ed
determin
iu
confid
interv
iu
use
probit
method
fig
tradit
mous
assay
use
live
wt
viru
shown
fig
ed
iu
ci
iu
confirm
serum
sampl
prior
viru
challeng
collect
test
vitro
neutral
activ
use
pbna
found
serum
sampl
pseudoviru
vivo
assay
show
complet
protect
neutral
antibodi
concentr
iuml
higher
two
anim
determin
dose
pseudoviru
inocul
serial
dilut
pseudovirus
inject
intraven
seven
group
mice
micegroup
anim
infecti
dose
aid
pseudoviru
found
tcid
pseudoviru
dose
determin
aid
equival
tcid
panel
visul
protect
potenc
hrigr
pseudoviru
vivo
assay
rabiesspecif
immunoglobulin
inject
km
mice
intramuscularli
three
day
challeng
either
wt
viru
pseudoviru
clear
doserespons
observ
pseudoviru
vivo
assay
panel
c
ed
curv
pseudoviru
assay
serum
sampl
antibodi
pbna
ed
determin
iu
confid
interv
iu
use
probit
method
panel
ed
curv
live
viru
modeland
serum
sampl
antibodi
tradit
mous
assay
use
live
wt
viru
ed
iu
ci
iu
scientif
report
doi
complet
protect
neutral
titer
found
iuml
live
viru
mous
model
full
protect
could
achiev
neutral
antibodi
level
iuml
greater
collect
data
indic
pseudoviru
vivo
assay
use
assess
effect
antirabi
antibodi
current
vitro
vivo
assay
rabi
vaccin
therapeut
rabiesspecif
immunoglobulin
requir
use
live
wt
rabi
viru
must
handl
level
biocontain
facil
addit
vivo
assay
take
least
two
week
known
labor
intens
clearli
explor
altern
method
facilit
develop
evalu
rabi
vaccin
therapeut
antibodi
pseudovirusbas
neutral
assay
pbna
offer
great
advantag
wt
virusbas
method
versatil
much
safer
handl
versatil
pseudoviru
achiev
pseudotyp
viru
differ
outer
membran
protein
envelop
protein
enabl
infect
varieti
cell
type
pseudoviru
much
safer
viru
essenti
devoid
virul
viral
compon
involv
singl
round
replic
yet
biggest
drawback
pseudoviru
system
harvest
virus
often
low
titer
substanti
limit
applic
particularli
vivo
studi
resolv
issu
systemat
analyz
type
promot
variou
combin
rabiesg
protein
express
plasmid
core
plasmid
express
luciferas
addit
optim
critic
step
highyield
pseudoviru
product
respect
reproduc
vitro
assay
pbna
also
reproduc
tradit
rffit
assay
demonstr
smaller
differ
valu
assign
two
intern
control
sampl
smaller
cv
valu
compar
assign
rffit
serum
titer
calcul
nation
standard
observ
good
agreement
valu
two
assay
howev
pbna
object
less
labor
intens
data
obtain
luminesc
read
oper
rffit
read
result
manual
microscop
biodistribut
pseudoviru
mice
systemat
investig
given
spleen
liver
major
organ
clear
particl
blood
circul
biodistribut
pattern
rabi
pseudoviru
administ
intraven
expectedli
differ
wt
viru
model
viru
given
intramuscularli
latter
case
rabi
viru
reach
cn
retrograd
transport
rout
follow
spread
centrifug
along
autonom
sensori
nerv
peripher
organ
pseudoviru
model
bioluminesc
found
brain
hour
time
signal
densiti
began
declin
spleen
liver
suggest
pseudoviru
maintain
neurotrop
properti
nevertheless
spleen
known
biggest
reservoir
monocyt
outnumb
circul
human
mous
monocyt
suscept
rabi
viral
infect
could
also
explain
strong
luminesc
signal
spleen
expect
intracerebr
inject
anim
pseudoviru
bioluminesc
signal
initi
found
mainli
local
brain
follow
redistribut
spleen
liver
biodistribut
pattern
similar
live
wt
viru
given
intracerebr
data
shown
therefor
differ
viral
biodistribut
larg
due
rout
administr
despit
differ
viral
distribut
data
gener
pbna
vivo
assay
demonstr
strong
statist
correl
obtain
live
wt
virusbas
assay
short
pbna
vitro
vivo
assay
superior
wt
virusbas
assay
specif
absenc
lethal
wt
viru
whole
experiment
procedur
could
greatli
facilit
develop
rabi
vaccin
therapeut
addit
pseudoviru
vitro
assay
sensit
reproduc
well
less
laborintens
compar
tradit
assay
moreov
pbna
vivo
assay
shorten
experiment
time
week
day
nonetheless
method
prepar
hightit
pseudoviru
optim
vitro
vivo
assay
could
interest
vaccin
develop
regul
alik
vero
atcc
cell
maintain
co
environ
high
glucos
dmem
gibco
supplement
fb
gibco
penicillin
iuml
streptomycin
gml
passag
everi
day
rabv
challeng
standard
kindli
provid
institut
pasteur
pari
franc
passag
bsr
establish
primari
master
work
viru
seed
lot
work
seed
use
rffit
live
viru
anim
model
rabiesneg
human
serum
sampl
kindli
provid
shanghai
raa
blood
product
co
ltd
shanghai
china
specif
determin
rabi
pbna
postvaccin
human
serum
sampl
collect
phase
iii
clinic
trial
rabi
vaccin
produc
vero
cell
chinadrugtri
govcn
id
kindli
provid
hualan
biolog
engin
inc
henan
china
healthi
volunt
receiv
rabi
vaccin
intramuscularli
day
dose
dose
dose
serum
sampl
collect
day
second
vaccin
collect
day
nation
standard
antirabi
immunoglobulin
collect
postvaccin
individu
establish
calibr
intern
standard
antirabi
immunoglobulin
human
nibsc
code
rai
two
serum
sampl
use
intern
control
rffit
also
collect
postvaccin
individu
calibr
use
intern
standard
assign
valu
nation
standard
iuml
assign
valu
intern
control
sampl
b
iuml
iuml
averag
sd
respect
written
inform
consent
obtain
volunt
fluc
scmvfluc
pscmvfluc
amplifi
clone
respect
env
gener
envfluc
use
restrict
endonucleas
digest
hpa
direct
ligat
infus
similarli
scmvfluc
construct
gener
envscmvfluc
primer
use
section
list
tabl
accomplish
use
method
similar
hiv
pseudoviru
describ
previous
briefli
mammalian
cell
cotransfect
rabi
g
protein
express
plasmid
hiv
backbon
vector
use
lipofectamin
invitrogen
carlsbad
ca
accord
manufactur
instruct
fortyeight
hour
post
transfect
pseudoviruscontain
cultur
supernat
harvest
filter
pore
size
store
lower
aliquot
use
tissu
cultur
infecti
dose
tcid
rabi
pseudoviru
batch
determin
use
singleus
aliquot
pseudoviru
bank
stock
use
avoid
inconsist
could
result
repeat
freezingthaw
cycl
serial
dilut
dilut
total
made
hexapl
well
cultur
plate
initi
dilut
last
column
design
neg
control
without
pseudoviru
trypsintr
mammalian
cell
adjust
concentr
mix
deaedextran
seed
well
h
incub
co
environ
cultur
medium
aspir
gentli
leav
l
well
l
brightglo
luciferas
reagent
promega
madison
wi
ad
well
follow
min
incub
room
temperatur
l
lysat
transfer
solid
black
plate
luminesc
detect
use
glomax
micropl
luminomet
promega
fitchburg
wi
tcid
calcul
use
reedmuench
method
vitro
pbna
neutral
measur
reduct
luc
gene
express
describ
previous
hiv
pseudoviru
neutral
assay
inhibitori
concentr
ic
defin
serum
dilut
rel
light
unit
rlu
reduc
compar
viru
control
well
viru
cell
subtract
background
rlu
control
group
cell
brief
pseudoviru
incub
serial
dilut
test
sampl
dilut
stepwis
manner
duplic
hour
togeth
viru
control
cell
control
well
hexapl
freshli
trypsin
cell
ad
well
follow
hour
incub
co
environ
luminesc
measur
describ
section
pseudoviru
titrat
ic
valu
calcul
nonlinear
regress
ie
log
inhibitor
vs
respons
four
paramet
use
graphpad
prism
graphpad
softwar
inc
san
diego
ca
neutral
antibodi
titer
calcul
compar
nation
antirabi
standard
iuml
sampl
neutral
antibodi
titer
equal
iuml
defin
adequ
protect
rabi
therefor
determin
posit
neutral
antibodi
titer
genuin
rabi
viru
determin
rffit
describ
previous
briefli
l
ffu
well
incub
l
serial
dilut
test
sampl
dilut
stepwis
manner
duplic
anim
experi
mice
hous
maintain
accord
relev
nation
guidelin
regul
procedur
carri
accord
protocol
approv
institut
anim
care
use
committe
nation
institut
food
drug
control
nifdc
anim
obtain
institut
laboratori
anim
resourc
nifdc
mice
inocul
human
rabi
immunoglubin
hrig
intramuscularli
three
day
viru
challeng
bled
viru
challeng
neutral
titer
mous
serum
sampl
determin
use
rabi
pbna
pseudoviru
vivo
challeng
assay
mice
inocul
differ
volum
pseudovirus
ie
ml
intramuscularli
ml
intracerebr
ml
subcutan
intraven
wt
viru
challeng
assay
mice
inocul
volum
ml
ld
intramuscularli
pseudoviru
challeng
assay
bioluminesc
detect
mous
wt
viru
challeng
surviv
rate
sign
rabi
record
group
time
period
day
challeng
vivo
bioluminesc
imag
analysi
bioluminesc
analys
conduct
use
ivislumina
iii
imag
system
xenogen
baltimor
md
describ
previous
briefli
mice
anesthet
intraperiton
ip
inject
pentobarbit
sodium
mgkg
bodi
weight
follow
ip
inject
substrat
dluciferin
gg
bodi
weight
xenogencalip
corp
alameda
ca
seven
minut
later
bioluminesc
detect
mous
imag
chamber
acquisit
time
min
rel
bioluminesc
calcul
use
photonpersecond
mode
normal
imag
area
photonss
cm
sr
total
flux
previous
describ
statist
analysi
one
way
analysi
varianc
use
assess
differ
pseudoviru
titer
gener
variou
cell
line
differ
cell
number
pair
comparison
also
conduct
use
student
test
pair
x
test
mcnemar
x
test
kappa
valu
use
assess
differ
qualit
result
obtain
pbna
rffit
pearson
correl
coeffici
employ
analyz
strength
linear
log
transform
valu
pbna
rffit
compar
quantit
result
obtain
posit
sampl
detect
assay
fit
regress
model
compar
test
twotail
hypothesi
slope
intercept
blandaltman
method
ie
scatter
plot
differ
pair
measur
mean
valu
sampl
use
assess
magnitud
disagr
two
assay
graph
gener
use
prism
softwar
graphpad
san
diego
ca
